Table 3.
Cure Rates for Hospital-Acquired Pneumonia at Follow-up/Test-of-Cure Visit
| Study, analysis population | Telavancin group,% (proportion) of patients | Vancomycin group, a% (proportion) of patients | Treatment difference,% of patients (95% CI) |
| Study 0015 | |||
| AT | 57.5 (214/372) | 59.1 (221/374) | −1.6 (–8.6 to 5.5) |
| CE | 83.7 (118/141) | 80.2 (138/172) | 3.5 (–5.1 to 12.0) |
| Study 0019 | |||
| AT | 60.2 (227/377) | 60.0 (228/380) | 0.2 (–6.8 to 7.2) |
| CE | 81.3 (139/171) | 81.2 (138/170) | 0.1 (–8.2 to 8.4) |
| Pooled data | |||
| AT | 58.9 (441/749) | 59.5 (449/754) | −0.7 (–5.6 to 4.3) |
| CE | 82.4 (257/312) | 80.7 (276/342) | 1.7 (–4.3 to 7.7) |
| ME | 79.0 (192/243) | 76.8 (182/237) | 2.2 (–5.2 to 9.7) |
NOTE. AT, all-treated population; CE, clinically evaluable population; CI, confidence interval; ME, microbiologically evaluable population.
a
Includes 20 AT patients and 6 CE patients who received antistaphylococcal penicillins instead of vancomycin.